ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 7.69 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $121.98 million which missed the analyst consensus estimate of $122.67 million by 0.56 percent. This is a 13.80 percent increase over sales of $107.19 million the same period last year.